VRXA
Veraxa Biotech AG (VRXA) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (F). The rating has held at D+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | F (0.0) | C+ (2.5) | B- (2.9) | D- (1.0) | C+ (2.6) | D+ (1.8) |
| 2026-11-08 | F (0.0) | C+ (2.5) | B- (2.9) | D- (0.8) | C+ (2.6) | D+ (1.8) |
| 2026-11-01 | F (0.0) | C+ (2.5) | B- (2.9) | D- (1.0) | C+ (2.7) | D+ (1.8) |
| 2026-10-25 | F (0.0) | C+ (2.5) | B- (2.9) | F (0.7) | C+ (2.6) | D+ (1.7) |
| 2026-10-18 | F (0.0) | C+ (2.5) | B- (2.9) | D- (0.8) | C+ (2.6) | D+ (1.8) |